Weekly Analysts’ Ratings Updates for Edwards Lifesciences (EW)

Edwards Lifesciences (NYSE: EW) has recently received a number of price target changes and ratings updates:

• 2/11/2026 – Edwards Lifesciences was given a new $89.00 price target by Truist Financial Corporation. They now have a “hold” rating on the stock.
• 2/11/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $95.00 price target on the stock, down from $108.00.
• 2/11/2026 – Edwards Lifesciences had its “overweight” rating reaffirmed by Piper Sandler. They now have a $100.00 price target on the stock, up from $98.00.
• 2/11/2026 – Edwards Lifesciences had its price target raised by Wells Fargo & Company from $96.00 to $100.00. They now have an “overweight” rating on the stock.
• 2/11/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by BTIG Research. They now have a $103.00 price target on the stock.
• 2/4/2026 – Edwards Lifesciences had its “neutral” rating reaffirmed by UBS Group AG. They now have a $94.00 price target on the stock.
• 1/21/2026 – Edwards Lifesciences had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 1/20/2026 – Edwards Lifesciences was given a new $110.00 price target by Stifel Nicolaus. They now have a “buy” rating on the stock.
• 1/20/2026 – Edwards Lifesciences had its “overweight” rating reaffirmed by Piper Sandler. They now have a $98.00 price target on the stock, up from $95.00.
• 1/12/2026 – Edwards Lifesciences had its “neutral” rating reaffirmed by UBS Group AG. They now have a $95.00 price target on the stock, up from $92.00.
• 1/12/2026 – Edwards Lifesciences was given a new $90.00 price target by Robert W. Baird.
• 1/12/2026 – Edwards Lifesciences had its “overweight” rating reaffirmed by Barclays PLC. They now have a $104.00 price target on the stock, up from $103.00.
• 1/9/2026 – Edwards Lifesciences was upgraded by TD Cowen from “hold” to “buy”.
• 1/9/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $108.00 price target on the stock.
• 1/9/2026 – Edwards Lifesciences was upgraded by TD Cowen from “hold” to “buy”. They now have a $97.00 price target on the stock, up from $90.00.
• 1/7/2026 – Edwards Lifesciences had its price target raised by Stifel Nicolaus from $100.00 to $105.00. They now have a “buy” rating on the stock.
• 1/5/2026 – Edwards Lifesciences had its “outperform” rating reaffirmed by Evercore Inc. They now have a $94.00 price target on the stock.

Insiders Place Their Bets

In related news, CFO Scott B. Ullem sold 7,700 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 79,144 shares of company stock valued at $6,685,688 in the last ninety days. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.